Uxn

UXN's business is entirely concentrated on a single product line: the enzyme-free Automatic Glucose Monitoring System (AGMS), making it a pure-play R&D model. In October 2016 the company absorbed nano-porous platinum manufacturer Nomadien, internalizing core material capabilities.

The current commercialization target is the third-generation model 'A2', which achieved a Mean Absolute Relative Difference (MARD) below 7% in animal trials, surpassing Abbott's FreeStyle Libre 3 (MARD 7.9%).

Because platinum is chemically stable, unlike enzymes, sensor accuracy does not degrade over time, and the device can be stored and transported at room temperature—an advantage particularly relevant in emerging markets lacking cold-chain infrastructure.

The product roadmap calls for a sequential expansion from a 7-day health-checkup version to a 14-day personal use device and eventually an implantable long-term CGM. Globally, Dexcom and Abbott dominate the CGM duopoly; domestically, i-SENS and IOflow have entered with enzyme-based products.

UXN differentiates itself through foundational technology rather than competing on manufacturing scale or distribution, but the company remains in the pre-revenue clinical development stage. The workforce stands at roughly 28 employees as of 2025, reflecting its small-scale R&D-focused structure.

Based on H1 2024 disclosures, UXN reported revenue of approximately KRW 240mn, operating loss of KRW 3.22bn, and net loss of KRW 1.55bn.

Total equity stands at -KRW 20.71bn (complete capital impairment), with total liabilities of KRW 52.32bn; current liabilities alone approach KRW 51.4bn against cash and equivalents of just KRW 1.24bn, indicating a critically thin liquidity buffer.

The root cause of this deterioration is the sustained R&D deficit since listing, compounded by successive rounds of external financing.

SD Biosensor invested a total of KRW 40bn in September 2021—including a KRW 18bn BW—to become the largest shareholder at 22.16%, but in October 2024 filed a court order demanding repayment of the BW principal (~KRW 19.62bn), triggering an acrimonious legal dispute accompanied by UXN's allegations of technology misappropriation.

The conflict was resolved in January 2025 when SD Biosensor agreed to convert all its RCPS to common shares and UXN agreed to pay 75% of the BW principal.

As of June 7, 2026, the share price stands at KRW 6,400 (+3.23% day-on-day), with a minimal market cap and daily average turnover of roughly KRW 15mn, reflecting very low KONEX liquidity.

In April 2026, media reports noted that the MFDS had classified UXN's product as a Class 3 medical device and that the review period—unusually long by industry standards—reflected the product's degree of innovation.

UXN has publicly declared 2026 as the target year for obtaining domestic product approval for the world's first platinum-based CGM.

Alongside this, the company executed a dual-track strategy in January 2026 by signing an MOU with King Faisal University (KFU) in Saudi Arabia and initiating detailed clinical trial steps locally.

The rationale for the Middle East pivot is to establish a beachhead in a relatively uncontested market before tackling the US duopoly. Room-temperature storage capability gives the platinum CGM a structural logistics advantage in markets with limited cold-chain infrastructure.

The company has set a long-term goal of capturing over 10% of the global CGM market within five years of commercialization—a target approaching Abbott's current market share that will require rigorous market validation.

The mid-to-long-term roadmap also includes a 14-day personal-use CGM and eventually an implantable version, providing multiple growth vectors post-approval.

However, the complete capital impairment and minimal cash balance create persistent refinancing risk, and regulatory timelines under MFDS Class 3 review remain a key variable.